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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.029Although myeloid cell activation is requisite for an optimal innate immune response, this process must be
tightly controlled to prevent collateral host tissue damage. Kruppel-like factor 2 (KLF2) is a potent
regulator of myeloid cell proinﬂammatory activation. As an approximately 30% to 50% reduction in KLF2
levels has been observed in human subjects with acute or chronic inﬂammatory disorders, we studied the
biological response to inﬂammation in KLF2þ/ mice. Herein, we show that partial deﬁciency of KLF2
modulates the in vivo response to acute (sepsis) and subacute (skin) inﬂammatory challenge. Mecha-
nistically, we link the anti-inﬂammatory effects of KLF2 to the inhibition of NF-kB transcriptional activity.
Collectively, the observations provide biologically relevant insights into KLF2-mediated modulation of
these inﬂammatory processes that could potentially be manipulated for therapeutic gain. (Am J Pathol
2013, 182: 1696e1704; http://dx.doi.org/10.1016/j.ajpath.2013.01.029)Supported by NIH grants HL097023 (G.H.M.), HL72952, HL75427,
HL76754, HL086548, and HL084154 (M.K.J.) and by American Heart
Association grant 11POST7200004 (N.S.).The process of inﬂammation is characterized by the recruit-
ment of macrophages to the site of injury.1 These cells are
derived from circulating monocytes and are plastic in nature,
with the ability to rapidly modulate their response to the local
microenvironment.2 In the initial phase of the injury re-
sponse, macrophages typically exhibit a proinﬂammatory
phenotype and release numerous cytokines, chemokines,
bactericidal agents, and reactive oxygen and nitrogen inter-
mediates to combat the source of inﬂammation.3,4 After
removal of the foreign agent, the macrophage also helps in
the resolution of inﬂammation and tissue healing.5 This
process must be carefully controlled, and unbridled inﬂam-
mation, perhaps due to an overexuberant or protracted
response, can lead to tissue injury and other untoward
systemic effects.6 Indeed, there is now compelling evidence
that low-grade chronic inﬂammation can contribute to
a broad spectrum of disease states, including dermatitis,
arthritis, metabolic disorders, and cardiovascular disease.7e9
Activation of the NF-kB pathway is central to the inﬂam-
mation and resolution phases of the innate immune
response.10 Gram-positive and Gram-negative bacterial cellstigative Pathology.
.wall components, such as lipoteichoic acid and lipopoly-
saccharide (LPS), induce Toll-like receptor signaling that
culminates in rapid activation of NF-kB followed by expression
of downstream target genes that initiate the initial inﬂamma-
tory response.11e13 Subsequently, NF-kB induces pathways
that, in a negative feedback manner, limit its activity and
facilitate the resolution of inﬂammation.14,15 Failure to limit
NF-kB activation leads to chronic inﬂammation, as has been
observed in inﬂammatory bowel disease,metabolic syndrome,
atherosclerosis, rheumatoid arthritis, and psoriasis.16e19 The
importance of this pathway is underscored by experimental
and clinical observations demonstrating that inhibition of the
NF-kBpathway (eg, through the use of anticytokine therapies)
can ameliorate disease.20e23
Kruppel-like factors (KLFs) are a subclass of the zinc-
ﬁnger family of DNA-binding transcription factors that
regulate diverse biological processes.24 KLF2 was initially
KLF2 Modulates Inﬂammationidentiﬁed by the Lingrel laboratory and was named for its
high expression in the lung.25 Subsequent work from our
group and others has implicated this factor as a negative
regulator of inﬂammation and NF-kB activity.26e28 Studies
in human subjects with inﬂammatory conditions, such as
sepsis, reveal that cellular levels of KLF2 are reduced by
approximately 30% to 50%.27 To recapitulate this experi-
mentally, we undertook studies in KLF2 hemizygous mice.
Our ﬁndings show that partial deﬁciency of KLF2 alters the
biological response in diverse models of acute inﬂamma-
tion. These ﬁndings, coupled with previous work in the
context of chronic inﬂammatory disease states, such as
atherosclerosis,29 speak strongly to the importance of KLF2
in the biological response to inﬂammation.
Materials and Methods
Materials
LPS, carrageenan, and phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) were purchased from Sigma-
Aldrich (St. Louis, MO). Recombinant mouse interferon g
(IFN-g) protein and tumor necrosis factor a (TNF-a)/
monocyte chemoattractant protein (MCP)-1 enzyme-linked
immunosorbent assay (ELISA) kits were obtained from
R&D Systems (Minneapolis, MN). A myeloperoxidase
colorimetric activity assay kit was obtained from BioVision
(Milpitas, CA). Thioglycolate broth and anti-MAC3 anti-
body were obtained from BD Pharmingen (Franklin Lakes,
NJ). Anti-B220/CD45R antibody was purchased from BD
Pharmingen and anti-CD3 antibody from Abcam Inc.
(Cambridge, MA). Rabbit polyclonal anti-p300 and anti-
PCAF antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA). The RAW264.7 cell line was
purchased fromATCC (Manassas, VA). A luciferase reporter
assay system was obtained from Promega (Madison,WI). All
other chemicals and reagents used were of analytical grade
and were obtained from commercial sources.
Cell Culture
Primary mouse macrophages were obtained from the perito-
neal cavity by inducing peritonitis with 3% thioglycolate broth
in 8- to 12-week-old mice as described earlier.27 These
primary peritoneal macrophages were maintained in Dulbec-
co’s modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum, 100 U/mL of penicillin, 100 mg/mL of strep-
tomycin, and 2 mm of glutamine in a humidiﬁed atmosphere
of 5% CO2 and 95% air at 37C. The RAW264.7 cell line was
used for in vitro experiments andwasmaintained under aseptic
conditions.
Experimental Mouse Models
The KLF2 hemizygous (KLF2þ/) mouse line used in this
study was generated as described previously.30 MouseThe American Journal of Pathology - ajp.amjpathol.orgcolonies used in this study were maintained in a clean animal
facility, and all animal experimentation was approved by the
Case Western Reserve University Institutional Animal Care
and Use Committee (Cleveland, OH).
TPA-Induced Cutaneous Inﬂammation Model
TPA-induced cutaneous inﬂammation experiments were
performed as described previously.31 Brieﬂy, ear fur from
wild-type (WT) and KLF2 hemizygous mice was removed 2
days before the experiment. The right ear was treated twice
at an interval of 24 hours with TPA (2.5 mg of TPA in 20 mL
of acetone). The left ear was treated similarly with acetone
alone and served as a control. The mice were sacriﬁced 24
hours after the second TPA application. Ear weight was
recorded using an analytical balance. The ear tissues were
either frozen to analyze myeloperoxidase activity or ﬁxed
with 4% paraformaldehyde to perform immunohistochem-
ical analysis using anti-MAC3 antibody to detect macro-
phage inﬁltration. Lymphoctye inﬁltration was also assessed
immunohistochemically using B-cell (anti-B220/CD45R
antibody) and T-cell (anti-CD3 antibody) markers.
Carrageenan-Induced Inﬂammation Model
A carrageenan-induced paw edema and inﬂammation
experiment was performed as described elsewhere.26 Brieﬂy,
the left hindfoot pads of WT and KLF2 hemizygous mice
were injected with 0.1 mL of 1% carrageenan (l-carra-
geenan, type IV). The right hindfoot pad received 0.1 mL of
saline and was used as control. After 24 hours of injection,
mice were euthanized and paw weight was recorded using an
analytical balance, and images were obtained. These paws
were ﬁxed in 4% paraformaldehyde, and immunohisto-
chemical analyses were performed using anti-MAC3 anti-
body to detect macrophage inﬁltration.
Thioglycolate-Induced Inﬂammation Model
WT and KLF2 hemizygous mice were subjected to
thioglycolate-induced peritonitis as described previously.27
Brieﬂy, WT and KLF2 hemizygous mice were injected
intraperitoneally with 1 mL of sterile 3% thioglycolate broth
per mouse. Mice were euthanized 72 hours after thio-
glycolate injection, and the peritoneal cavity was ﬂushed
with 5 mL of sterile PBS and 1 mL of air to harvest cells.
The total number of macrophages that responded to the site
of inﬂammation was counted as an indicator of inﬂamma-
tory status and was used for further biochemical analysis.
LPS-Induced Sepsis Model
WT and KLF2 hemizygous mice were subjected to the LPS-
induced sepsis model as described previously.27 Brieﬂy, WT
and KLF2 hemizygous mice were injected i.p. with 23 mg/kg
of LPS. These mice were monitored for rectal temperature,
blood pressure, and heart rate after LPS injection. Plasma
TNF-a and MCP-1 levels were quantiﬁed using an ELISA
kit. The shock index was determined using the following
formula: Shock IndexZHeart Rate/Systolic Blood Pressure.1697
Nayak et alSurvival data were analyzed by the construction of Kaplan-
Meier plots and use of the log-rank test.
Real-Time Quantitative RT-PCR and Luciferase Reporter
Assay
Total RNA was isolated from indicated cell types after
completion of the speciﬁed treatment using TRIzol reagent
(Invitrogen, Carlsbad, CA). One microgram of total RNA was
subjected to reverse transcription using Moloney Murine
Leukemia Virus Reverse Transcriptase (New England Bio-
labs, Ipswich, MA) in the presence of oligo-dT and random
hexamer primers. The resulting cDNA was subjected to real-
time quantitative PCR using gene-speciﬁc primers (Table 1)
and universal SYBRGreen PCRmaster mix on a StepOnePlus
real-time PCR system (Applied Biosystems, Foster City, CA).
Luciferase reporter plasmids driven by the inducible nitric
oxide synthase (iNOS) promoter (1.5 kb) or NF-kB con-
catemer were transfected alone or were cotransfected with
pcDNA3.1 or KLF2 plasmids in RAW264.7 cells using
FuGENE (Promega,Madison,WI) transfection reagent. These
cells were exposed to LPS or IFN-g after 24 hours of trans-
fection. Luciferase reporter activity was measured and
normalized with the luciferase reporter assay systems as
speciﬁed by themanufacturer’s instructions, and the results are
presented as relative luciferase activity over the control group.
Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation analyses were performed as
described previously27 using the EZ-Magna ChIP A kit
(Millipore Corp., Billerica, MA) according to the manu-
facturer’s instructions. RAW264.7 cells were infected with
Ad-KLF2 or Ad-GFP, and these cells were induced with
IFN-g or LPS. Chromatin was precipitated with anti-p65,
anti-p300, and anti-PCAF antibodies separately after IFN-g
or LPS treatment. These chromatin samples were analyzed by
PCR using primer pairs ﬂanking the NF-kB site targeted to
amplify mouse iNOS promoter (50 primer: 50-GGATGTG-
CTAGGGGGATTTT-30; 30 primer: 50-AATGTCCTACCT-
GGGTGTGG-30).Table 1 List of Primers Used for Quantitative PCR Analysis
Gene target Forward primer
KLF2 50-CTAAAGGCGCATCTGCGTA-30
KLF4 50-CGGGAAGGGAGAAGACACT-30
TNF 50-GACGTGGAAGTGGCAGAAGAG-30
COX2 50-CCAGCACTTCACCCATCAGTT-30
MCP1 50-CATCCACGTGTTGGCTCA-30
IFNG 50-ATCTGGAGGAACTGGCAAAA-30
IL6 50-GCTACCAAACTGGATATAATCAGGA-
NOS2 50-CTTTGCCACGGACGAGAC-30
IL1B 50-TTGACGGACCCCAAAAGAT-30
MCP2 50-TTCTTTGCCTGCTGCTCATA-30
MCP5 50-CCATCAGTCCTCAGGTATTGG-30
36B4 50-GCTCCAAGCAGATGCAGCA-30
1698Statistical Analysis
All the data are presented as means  SD unless indicated
otherwise. The statistical signiﬁcance of differences between
two groups was analyzed using Student’s t-test. P< 0.05 was
considered statistically signiﬁcant.Results
Deﬁciency of KLF2 Accelerates LPS-Induced Sepsis
Symptoms
Previous clinical studies in acute (sepsis)27 and chronic
(atherosclerosis)26 inﬂammatory disorders reveal an approxi-
mately 30% to 50%decrease in cellular KLF2 levels. Tomimic
this experimentally, we used KLF2 hemizygous mice in the
studies. No difference in the total white blood cell count or in
the differential count of white blood cells was observed
between control and KLF2 hemizygous mice (data not shown).
As expected, an approximately 50% reduction in macrophage
KLF2 was seen under basal conditions and after proin-
ﬂammatory (IFN-g or LPS) stimulation of macrophages from
KLF2 hemizygous mice (Supplemental Figure S1, A and B).
However, no signiﬁcant effect was seen on the expression of
KLF4, a secondmember of the family that has been implicated
in macrophage biology (Supplemental Figure S1C).
Next, we subjected WT and KLF2 hemizygous-deﬁcient
mice to LPS-induced sepsis. The hallmark features of
endotoxin-induced sepsis are hypothermia, hypotension, ex-
uberant cytokine production, and death. In response to the
LPS challenge, KLF2þ/ mice exhibited a reduced surface
body temperature as recorded by infrared thermal images
(Figure 1A). Assessment of core body temperature by rectal
probe indicated that KLF2 hemizygous mice reduced their
core body temperature by >3C compared with WT mice
and, indeed, experienced endotoxin-induced hypothermia
(Figure 1B). Analysis of systolic blood pressure of WT and
KLF2 hemizygous mice after LPS-induced sepsis indicated
that partial deﬁciency of KLF2 led to a signiﬁcant loss in
hemodynamic pressure and an increased shock index (Figure 1,
C and D). Analysis of plasma cytokines indicated that partialReverse primer
50-TAGTGGCGGGTAAGCTCGT-30
50-GAGTTCCTCACGCCAACG-30
50-TGCCACAAGCAGGAATGAGA-30
50-ACCCAGGTCCTCGCTTATGA-30
50-GATCATCTTGCTGGTGAATGAGT-30
50-TTCAAGACTTCAAAGAGTCTGAGGTA-30
30 50-CCAGGTAGCTATGGTACTCCAGAA-30
50-TCATTGTACTCTGAGGGCTGAC-30
50-GAAGCTGGATGCTCTCATCTG-30
50-AGCAGGTGACTGGAGCCTTA-30
50-CTTCCGGACGTGAATCTTCT-30
50-CCGGATGTGAGGCAGCAG-30
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Figure 1 Deﬁciency of KLF2-accelerated LPS-
induced sepsis symptoms. A and B: WT and KLF2
hemizygous mice were subjected to LPS-induced
sepsis by i.p. injection of LPS. Surface body
temperature was recorded by thermal infrared
camera (A), and core body temperature was
recorded by rectal probe (B). C and D: Age- and
sex-matched WT and KLF2 hemizygous mice were
subjected to LPS-induced sepsis and were moni-
tored for alteration in systolic blood pressure (tail
cuff blood pressure monitor system; C) and shock
index (D). E and F: WT and KLF2 hemizygous mice
were subjected to LPS-induced sepsis, and plasma
levels of TNF-a (E) and MCP-1 (F) were measured
by ELISA after 4 hours of LPS injection. G: Age-
and sex-matched WT and KLF2 hemizygous (HET)
mice were subjected to LPS-induced sepsis. The
mice were observed for 48 hours for survival. The
combined data from three experiments are shown
in each case. Data are presented as means  SD.
*P < 0.05 versus the indicated control group.
KLF2 Modulates Inﬂammationdeﬁciency of KLF2 leads to a signiﬁcant increase in proin-
ﬂammatory cytokines, such as TNF-a andMCP-1 (Figure 1, E
and F). Finally, KLF2 hemizygousmice demonstrated reduced
survival, with 100%mortality by 30 hours after LPS challenge.
However, WT mice exhibited signiﬁcantly better survival
rates, and 20% of mice continued to survive after endotoxic
insult (Figure 1G).Collectively, these data suggest thatKLF2 is
protective against LPS-induced sepsis and that a physiologic
level of deﬁciency of KLF2 can mimic human sepsis
conditions.
Deﬁciency of KLF2 Enhances LPS-Induced
Proinﬂammatory Gene Expression
Previous results have indicated that hemizygous deﬁciency of
KLF2 enhanced proinﬂammatory gene expression in response
to LPS stimulation in vivo. To determine whether this occurs in
a cell-autonomous manner, we studied macrophages from
control and KLF2þ/ mice. Peritoneal macrophages wereThe American Journal of Pathology - ajp.amjpathol.orgharvested and stimulated with LPS, and the expression of key
proinﬂammatorymolecules was analyzed. These data indicated
that LPS signiﬁcantly induced the expression of TNF-a,
cyclooxygenase-2, and MCP-1 in KLF2 hemizygous macro-
phages compared with WT macrophages treated with similar
conditions (Figure 2, AeC). Furthermore, partial deﬁciencies
in KLF2 also lead to a signiﬁcant increase in IFN-g, IL-6, and
iNOS expression compared with its WT counterpart after LPS
treatment (Figure 2, DeF). Taken together, these results are
consistent with the previous observation (Figure 1, E and F)
that hemizygous deﬁciency of KLF2 signiﬁcantly enhances
the expression of proinﬂammatory genes after inﬂammatory
stimuli.
Hemizygous Deﬁciency of KLF2 Augments Subacute
Inﬂammation
Next, we sought to extend the studies using models of subacute
inﬂammation, including phorbol ester TPAeinduced skin1699
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Figure 2 Deﬁciency of KLF2 enhanced LPS-
induced proinﬂammatory gene expression. AeC:
WT and KLF2 hemizygous peritoneal macrophages
were induced with 100 ng/mL of LPS, and total
RNA was analyzed for expression of critical
proinﬂammatory molecules, such as TNF-a (A),
cyclooxygenase-2 (COX-2) (B), and MCP-1 (C), and
was normalized to 36B4. DeF: Peritoneal macro-
phages derived from WT and KLF2 hemizygous
mice were subjected to 100 ng/mL of LPS stimu-
lation. Total RNA from these cells were extracted
and analyzed for expression of systemic inﬂam-
matory response syndrome mediators, such as
IFN-g (D), IL-6 (E), and iNOS (F). 36B4 was used
as an internal control. The combined data from
three experiments are shown in each case. Data
are presented as means  SD. *P < 0.05 versus
the indicated control.
Nayak et alinjury and carrageenan-induced paw edema. First, we applied
phorbol ester TPA to the right ear of WT and KLF2 hemi-
zygous mice. The left ear received only vehicle and served
as a control. One of the cardinal features of inﬂammation is
interstitial ﬂuid accumulation. To quantify levels of edema
induced by TPA, deﬁned portions of ears from WT and
KLF2 hemizygous mice were weighed after TPA stimula-
tion. As indicated in Figure 3A, hemizygous deﬁciency of
KLF2 exhibited signiﬁcantly increased ﬂuid accumulation.
In addition, as shown in Figure 3B, KLF2þ/ mice also
demonstrated massive myeloid cell accumulation (Mac3
staining). To quantify the status of myeloid cell inﬁltration,1700ears from WT and KLF2 hemizygous mice treated with
vehicle or TPA were subjected to myeloperoxidase activity
analysis. As shown in Figure 3C, hemizygous deﬁciency of
KLF2 signiﬁcantly enhanced TPA-induced myeloid cell
inﬁltration over the WT counterpart. Although macro-
phages form the dominant leukocyte to inﬁltrate the tissue,
TPA application to the ear can also be associated with
increased tissue inﬁltration with lymphocytes. However, no
signiﬁcant difference was noted in the total number of
lymphocytes that inﬁltrated the tissue in WT and KLF2
hemizygous mice either at baseline or with TPA application
(Supplemental Figure S1D).Figure 3 KLF2 modulated the progression of
cutaneous inﬂammation. A: WT and KLF2 hemizygous
mice were subjected to the TPA-induced cutaneous
inﬂammation model. Ear weights from the control
and experimental groups were recorded using an
analytical balance, and percentage increase in ear
weight compared with the control group is indicated.
B: WT and KLF2 hemizygous mice were subjected to
TPA-induced inﬂammation. Ear tissues from mice
from these experiments were immunohistochemically
analyzed using anti-MAC3 antibody for macrophage
localization. C: Total protein extracts from ear tissue
from mice derived through the TPA-induced inﬂam-
mation model were subjected to myeloperoxidase
(MPO) activity analysis, and data are presented as
MPO activity units/1 mg of total protein. DeF: Total
RNA was isolated from ears of WT and KLF2 hemi-
zygous mice that were subjected to the TPA-induced
inﬂammation model. Expression of IL-1b (D), IL-6
(E), and MCP-1 (F) was analyzed by quantitative
PCR and normalized to 36B4. The combined data from
three experiments are shown in each case. Data are
presented as means  SD. *P < 0.05 versus the
indicated control.
ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Deﬁciency of KLF2 enhanced
carrageenan-induced acute inﬂammation. A: WT
and KLF2 hemizygous mice were subjected to
carrageenan-induced acute inﬂammation. Paw
weights from the control and experimental groups
were recorded using an analytical balance, and
percentage increase in paw weight compared with
the control group is indicated. B and C: WT and
KLF2 hemizygous mice received 0.1 mL of saline or
1% carrageenan. The mice were euthanized, and
paw morphologic features of the control and
experimental group were documented (B). Paw
tissue from WT and KLF2 hemizygous mice from
carrageenan-induced inﬂammation experiments
were subjected to immunohistochemical analysis
using anti-MAC3 antibody (C). D: WT and KLF2
hemizygous mice were subjected to thioglycolate-
induced peritonitis. Total cells from the peritoneal
cavity were harvested using sterile PBS after 72
hours of thioglycolate injection and then were
counted. E and F: Peritoneal macrophages derived
from WT and KLF2 hemizygous mice were induced
with 5 ng/mL of IFN-g for 12 hours. MCP-2 (E) and
MCP-5 (F) mRNA expression was analyzed by
quantitative PCR and normalized to 36B4. The
combined data from three experiments are shown
in each case. Data are presented as means  SD.
*P < 0.05 versus the indicated control.
KLF2 Modulates InﬂammationFinally, we directly tested the role of KLF2 on inﬂam-
matory cytokine expression after TPA treatment. Total RNA
was extracted from ears from WT and KLF2 hemizygous
mice after TPA or vehicle treatment. Expression analysis of
key proinﬂammatory cytokines, such as IL-1b, IL-6, and
MCP-1, indicated that deﬁciency of KLF2 signiﬁcantly
enhanced the expression of these cytokines after TPA treat-
ment (Figure 3, DeF). Taken together, hemizygous deﬁ-
ciency of KLF2 signiﬁcantly enhanced TPA-induced key
proinﬂammatory cytokine expression, vascular instability,
interstitial ﬂuid accumulation, and macrophage inﬁltration.KLF2þ/ Mice Exhibit Enhanced Inﬂammation in the
Carrageenan-Induced Paw Edema Model
To determine whether the ﬁndings were recapitulated in
a second model, we expanded the analysis to the carrageenan-
induced paw edema model. Accordingly, WT and KLF2
hemizygous mice received 1% carrageenan or saline in the
hindlimb foot pad. As shown in Figure 4, A and B, hemi-
zygous deﬁciency of KLF2 mice exhibited a signiﬁcant
increase in paw edema compared with WT mice. Concordant
with this observation, immunohistochemical analysis indi-
cated that deﬁciency of KLF2 enhanced interstitial edema and
the cellular content of the inﬂammatory site (Figure 4C).
Taken together, these results indicate that deﬁciency of KLF2
enhances carrageenan-induced acute inﬂammation processes.The American Journal of Pathology - ajp.amjpathol.orgThe observations from these two independent experi-
mental models indicate that deﬁciency of KLF2 resulted in
increased localization of innate immune cells at the site of
inﬂammation. This further prompted us to examine the role
of KLF2 in the recruitment of myeloid cells during the
process of inﬂammation. Peritonitis is a well-known path-
ologic process characterized by massive inﬁltration of
myeloid cells. In this model, the macrophage is the primary
cellular constituent in peritoneal exudates 72 to 96 hours
after thioglycolate treatment.32 Accordingly, WT and KLF2
hemizygous mice were subjected to thioglycolate-induced
peritonitis, and the total number of macrophages that
accumulated at the site of inﬂammation were counted as an
indicator of the inﬂammatory status. The results demonstrate
that hemizygous deﬁciency of KLF2 was associated with
signiﬁcantly enhanced recruitment of macrophages to the
site of inﬂammation at 72 hours compared with the WT
group (Figure 4D). These macrophages isolated from WT
and KLF2 hemizygous mice were cultured and induced with
IFN-g for 12 hours. Gene expression analysis indicated that
IFN-geinduced proinﬂammatory cytokines, such as MCP-2
and MCP-5, were signiﬁcantly induced in KLF2 hemizygous
mice compared with their WT counterparts (Figure 4, E and
F). Collectively, these results indicate that partial deﬁciency
of KLF2 signiﬁcantly enhances the processes of acute
inﬂammation through augmentation of proinﬂammatory
gene expression and macrophage recruitment at the site of
inﬂammation.1701
Figure 5 KLF2 negatively regulated proinﬂammatory gene expression by
modulating recruitment of critical NF-kB coactivators. A: RAW264.7 cells
were cotransfected with NF-kB concatemer luciferase reporter plasmid in the
presence of KLF2 or pcDNA3.1. These cells were stimulated with IFN-g or LPS,
and induction in luciferase was documented and is indicated as relative
luciferase activity over the control group. B and C: RAW264.7 cells were
cotransfected with iNOS promoter luciferase reporter plasmid in the presence
of KLF2 or pcDNA3.1. These cells were stimulated with IFN-g or LPS for 12
hours, and luciferase activity was measured and is indicated as relative
luciferase activity over control (B). RAW264.7 cells were transfected with
pcDNA3.1 or KLF2 plasmid and stimulated with IFN-g or LPS for 12 hours.
Total RNA from these cells was isolated, and iNOS mRNA expression was
analyzed by quantitative PCR and normalized to 36B4 (C). D: RAW264.7 cells
infected with Ad-GFP or Ad-KLF2 were stimulated with LPS for 45 minutes.
Chromatin immunoprecipitation was performed using the indicated antibody
on the iNOS promoter ﬂanking the NF-kB binding site. The combined data
from three experiments are shown in each case. Data are presented as
means  SD. *P < 0.05 versus the indicated control.
Nayak et alKLF2 Negatively Regulates Proinﬂammatory Gene
Expression by Modulating Recruitment of Critical
NF-kB Coactivators
The studies thus far indicate that partial KLF2 deﬁciency
induces the expression of proinﬂammatory genes, such as
iNOS, MCP-1, IL-6, IFN-g, and cyclooxygenase-2, after
chronic and acute inﬂammatory stimuli.27 All these proin-
ﬂammatory genes are known to be regulated at the transcrip-
tional level by the NF-kB signaling pathway.33 Therefore, we
hypothesized that KLF2might regulate proinﬂammatory gene
expression after inﬂammatory stimuli through modulation of
NF-kB transcriptional activity. Accordingly, RAW264.7 cells
were cotransfected with NF-kB luciferase reporter plasmid in
the presence or absence of KLF2. These cells were stimulated
with IFN-g or LPS, and luciferase activity was measured. The
results indicate that IFN-g and LPS strongly induce NF-kB
transcriptional activity in the RAW264.7macrophage cell line
(Figure 5A). However, overexpression of KLF2 signiﬁcantly
attenuates IFN-ge or LPS-induced NF-kB transcriptional
activity.1702These observations prompted us to examine the parallel
effect of KLF2 on NF-kB target genes. One of the well-
studied NF-kB target genes that is known to be induced by
chronic (IFN-g) and acute (LPS) inﬂammatory stimuli is
iNOS.34,35 To examine the role of KLF2 in the regulation of
iNOS expression after IFN-g or LPS treatment, RAW264.7
cells were cotransfected with the iNOS promoter luciferase
reporter plasmid (1.5 kb) in the presence or absence of
KLF2. These cells were induced with IFN-g or LPS, and
luciferase activity was documented. The results demonstrate
that overexpression of KLF2 signiﬁcantly attenuated IFN-
ge and LPS-induced iNOS promoter activity (Figure 5B).
Concordant with this observation, overexpression of KLF2
signiﬁcantly diminished IFN-ge or LPS-induced iNOS
mRNA expression in the RAW264.7 macrophage cell line
(Figure 5C). These two independent results suggest that
KLF2 modulates proinﬂammatory gene expression through
modulation of NF-kB transcriptional activity. To test this
hypothesis RAW264.7 cells were infected with Ad-KLF2 or
Ad-GFP and were stimulated with IFN-g or LPS for 45
minutes. Total chromatin from these sampleswas isolated and
subjected to chromatin immunoprecipitation with antieNF-
kB p65 antibody or critical coactivators of NF-kB, such as
anti-p300 and anti-PCAF antibody. Induction of RAW264.7
cells with IFN-g or LPS strongly enhanced NF-kB p65
recruitment to iNOS promoter (Figure 5D). Overexpression
of KLF2 did not alter IFN-ge or LPS-induced p65 recruit-
ment to iNOS promoter. However, KLF2 strongly attenuated
IFN-geor LPS-induced p300 andPCAF recruitment to iNOS
promoter. Taken together, these results indicate that KLF2
regulates NF-kB transcriptional activity by modulating crit-
ical NF-kB coactivator recruitment.Discussion
The ﬁndings of this study are that i) KLF2 negatively regu-
lates LPS-induced sepsis symptoms, endotoxic shock, and
mortality; ii) TPA-induced cutaneous chronic inﬂammation
is enhanced in KLF2 hemizygous mice; iii) hemizygous
deﬁciency of KLF2 augments carrageenan-induced acute
inﬂammation; iv) deﬁciency of KLF2 enhances TPA-, IFN-
ge, and LPS-induced proinﬂammatory gene expression; and
v) KLF2 negatively regulates NF-kB transcriptional activity
and targets gene expression through modulating recruitment
of critical NF-kB coactivators. Collectively, these observa-
tions implicate KLF2 as a major regulator of chronic and
acute inﬂammation. KLF2 modulates these pathophysiologic
processes by coordinating NF-kB transcriptional activity and
proinﬂammatory gene expression.
The past decade has been witness to a growing appreci-
ation that members of the KLF gene family are essential
regulators of inﬂammation.36 Among the many family
members, KLF2 has emerged as being particularly impor-
tant in this regard.30 Studies from our group and others have
revealed a broad expression pattern for KLF2 in numerousajp.amjpathol.org - The American Journal of Pathology
KLF2 Modulates Inﬂammationcell types, including endothelial cells, epithelial cells,
lymphocytes, and myeloid cells.24 A consistent feature of
this factor across these diverse cell types is that expression is
reduced in response to proinﬂammatory stimuli.27,37,38
These observations led to the hypothesis that KLF2 may
serve as a negative regulator of inﬂammation and that down-
regulation would unleash a vigorous inﬂammatory response.
Indeed, gain- and loss-of-function studies in cell culture
studies support this consideration.26 In vivo validation has
been more difﬁcult because systemic deﬁciency of KLF2 is
lethal,39 thereby necessitating conditional approaches.40 For
example, T-cellespeciﬁc knockout of KLF2 reveals an
essential role for this factor in T-cell development, homing,
and activation. Although KLF2 expression is maintained in
peripheral naive T cells, it is rapidly lost on T-cell activa-
tion. KLF2-deﬁcient thymocytes also display activation
markers suggesting that KLF2 is important for maintaining
naive T-cell quiescence.36 In a parallel manner, myeloid-
speciﬁc deletion of KLF2 has also been implicated as
essential for cellular quiescence and activation.27 Albeit
these studies are elegant and informative, there are some
limitations. For example, rarely in biology is the expression
of a speciﬁc factor completely eliminated, as is the case with
conditional deletion studies. Indeed, we and others have
reported that KLF2 levels are reduced by approximately
30% to 50% in human subjects during states of acute and
chronic inﬂammation.26,27 We sought to recapitulate this
ﬁnding experimentally using KLF2 hemizygous mice. The
central ﬁnding of this study is that a 50% reduction in KLF2
levels is associated with enhanced acute and subacute
inﬂammatory responses. Speciﬁcally, we demonstrate that
cellular cytokine/chemokine and iNOS production was
increased in KLF2þ/ cells, suggesting that the partial
absence of KLF2 allows for more exuberant inﬂammatory
activation. The in vivo importance of this is seen in models
of acute local (ear injury, paw edema) and systemic (sepsis)
inﬂammation. In the latter case, the consequences of this
overly exuberant activation are signiﬁcant and culminate in
reduced survival. We note that although the enhanced
recruitment of KLF2þ/ macrophages seen herein has also
been observed in previous publications,41 an increase in
recruitment has been observed in KLF2 overexpression
studies. Although these ﬁndings seem discordant, the results
likely reﬂect the fact that the experimental systems are quite
different. In this study, we used primary KLF2þ/ mice,
whereas Das et al26 injected irradiated C.B-17-Scid-beige
mice deﬁcient in T, B, and natural killer cells with J774a
cells that were adenovirally infected with KLF2. Regardless,
the results herein strongly support the notion that a physio-
logic level of decrease in KLF2 levels may signiﬁcantly
enhance chronic inﬂammatory disease processes.
Previous studies from our group indicated that KLF2 levels
are signiﬁcantly attenuated in immune cells after proin-
ﬂammatory stimuli, such as LPS.26 Furthermore, in vitro
analysis of KLF2 hemizygous macrophages demonstrated
signiﬁcantly elevated levels of proinﬂammatory mediators,The American Journal of Pathology - ajp.amjpathol.orgsuch as cyclooxygenase-1, MCP-1, TNF-a, and iNOS, after
LPS stimulation.27 All these proinﬂammatory genes are direct
downstream targets of NF-kB. The present study, in addition
to our previous work, provides mechanistic insights into these
observations. Herein, we demonstrate that KLF2 alters NK-kB
activity by affecting coactivator recruitment to its target genes.
Thus, although sustained elevation of KLF2 levels did not
affect recruitment of NF-kB p65 itself on iNOS promoter,
overexpression of KLF2 attenuated p300 and PCAF recruit-
ment to the iNOS promoter in macrophages.
In summary, these ﬁndings support the biological impor-
tance of amoderate reduction inKLF2 in themyeloid response
to acute inﬂammation. These results add to previous work
showing that hemizygous deﬁciency of KLF2 is also impor-
tant in thedevelopment of chronic inﬂammatory disease states,
such as atherosclerosis or arthritis.29,41 Atkins et al29 showed
that KLF2þ/ mice on an apolipoprotein Eenull background
develop enhanced atherosclerotic lesions. Furthermore, Das
et al41 showed that KLF2þ/ mice exhibit increased suscep-
tibility to bone and cartilage destruction after intra-articular
challenge with methylated bovine serum albumin or IL-1b.
Collectively, these studies speak cogently to the physiologic
importance of KLF2 in the inﬂammatory response.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.01.029.
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